Loading
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Precision Biologics, Inc, active and no longer recruiting.
Study of NEO-201 in Solid Tumors Expansion Cohorts is a phase 1/2 interventional study registered as NCT03476681 by Precision Biologics, Inc, with 121 participants planned, started 2019-01-18 and due to reach its primary completion in 2026-06-17. Interventions recorded: NEO-201 in combination with pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/